The Effectiveness of Tecar Therapy in Management of Calf Muscle Strain Injuries (MS)
25 avril 2026 mis à jour par: Nabil Mahmoud Ismail Abdel-Aal, Cairo University
this study will be conducted to investigate the effect of TECAR Therapy on quality of landing, healing and Function in patient with Calf Muscle Strain.
Aperçu de l'étude
Statut
Pas encore de recrutement
Les conditions
Intervention / Traitement
Description détaillée
Calf muscle strain is one of the most common muscle injuries in high-performance athletes and contributes to substantial player downtime because of its high mean time to return to sport and occurrence during critical periods in the competitive season.
Published reports on lower-body muscle strain have provided frequent updates on the rehabilitation of high-profile muscle groups, such as the hamstring muscles, and improvements to calf strain management are seldom discussed despite the prevalence of these injuries in competitive sports.
In this article, we discuss the diagnosis, treatment, outcomes, risk factors, and prevention of calf muscle strain in athletes.Transfer of Electricity-Capacitive and Resistive (Tecar) therapy is considered a special form of energy that uses frequencies between 300 KHz and 1 MHz and is characterized as a non-invasive high-frequency energy that awakens the body's natural ability to self-regenerate.
Thus, it promotes the natural physiological processes of the tissue metabolically, transferring energy without introducing radiation from the external environment.
TECAR therapy stands out as a promising yet underexplored modality.
Its mechanism of action-utilizing both capacitive and resistive energy transfer-suggests a novel approach to addressing musculoskeletal injuries and pain.
While preliminary studies and clinical applications hint at its potential advantages, such as improved tissue healing and pain relief, a comprehensive evaluation of the existing research is necessary to fully understand the role of TECAR therapy in rehabilitation
Type d'étude
Interventionnel
Inscription (Estimé)
60
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Coordonnées de l'étude
- Nom: Nabil Abdel-Aal, professor
- Numéro de téléphone: 01200133613
- E-mail: nabil.mahmoud@cu.edu.eg
Sauvegarde des contacts de l'étude
- Nom: Hossam Mostafa, master
- Numéro de téléphone: 01092727746
- E-mail: h.elshatory@gmail.com
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
Accepte les volontaires sains
Non
La description
Inclusion Criteria:
- Aged between 16-39 years of age.
- not having suffered leg injuries in the past 6 months.
- not having suffered a triceps sural rupture in the past two years.
- be diagnosed with latent MTPs in the gastric-soleus complex through manual therapy in the dominant side.
- Presence of Calf muscles Strain evaluated by Ultrasonography.
- Athlete willing and able to participate in an exercise program safely.
- The radiologist also assessed whether the tendon ends could be reduced in passive plantar flexion of the ankle joint with the knee extended.
- Athlete BMI from 18.5 to 24.9 kg / m2
Exclusion Criteria:
- connective tissue pathology.
- lymphatic disorders (lymphadenopathy).
- Skin injuries (open wounds, infection, psoriasis, tattoos, hematoma).
- peripheral neuropathies.
- previous fractures.
- previous lower limb surgeries (in the past 12 months).
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: TECAR therapy
Thirty patients will receive TECAR therapy combined with conventional treatment three times per week for 12 weeks.
|
The TECAR intervention was administered to the calf muscle using the Zimmer devicein capacitive (CAP) mode for a duration of 20 min.
The therapy was applied with the signal at a variable power with a maximum of 300 W. The frequency used was 500 kHz with an intensity of 40%.
The intervention was standardized to a distal-to-proximal stroking rhythm with moderate pressure.
For the TECAR intervention, the capacitive (CAP) mode at 500 kHz with 40% intensity and a maximum power of 300 W was chosen to optimize deep tissue heating and promote local blood flow and tissue recovery.
The 20 min duration reflects protocols commonly used in therapeutic settings for muscle recovery and rehabilitation plus conventional therapy
the patients will receive stretching exercises of the gastrocnemius (straight leg) and soleus (bended knee), eccentric exercises for calf muscles, plus plyometric exercises.
|
|
Comparateur actif: conventional treatment
Thirty patients will receive conventional treatment three times per week for 12 weeks.
|
the patients will receive stretching exercises of the gastrocnemius (straight leg) and soleus (bended knee), eccentric exercises for calf muscles, plus plyometric exercises.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
size of injury
Délai: up to 12 weeks
|
ultrasonography device will be used to assess size of injury
|
up to 12 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
landing error score system
Délai: up to 12 weeks
|
Landing Error Scoring System is a clinical tool used to assess jump-landing mechanics for the video from my jumb land aplication .
the feet, ankle, knees, hip, trunk, shoulder, neck and head posture is assessed through the video.
it is a 17-item .
According to the performance sheet, the questions 1-15 are Yes/No questions that are rated as 0 or 1.
The questions 16 are rated as 0, 1, and 2; 0 = soft, 1= average and 2= stiff.
the question 17 are rated as 0,1,2; 0= excellent,1 average and 2= poor, so the total score ranges from zero to 19.
A higher score indicates poor technique in landing from a jump; a lower score indicates better jump-landing technique.
the score are categorized as excellent which less than 4, good score more than four and less than or equal 5, moderate score less than four and poor more than six
|
up to 12 weeks
|
|
jump height
Délai: up to 12 weeks
|
The vertical jump test was performed as a one-legged counter movement jump (CMJ).
Starting position was in an upright position with the hands placed behind the back.
The subjects quickly bent the knee as much as desired and then immediately jumped upward attempting to maximize the height jumped.
The subjects performed three maximal approved trials for each leg, starting with the right and alternating between the right and the left leg.
However, if the subject increased hop performance in all three jumps, additional jumps were performed until no increase was seen.
The best jump height for each leg was used for data analysis.
|
up to 12 weeks
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Estimé)
1 mai 2026
Achèvement primaire (Estimé)
1 décembre 2026
Achèvement de l'étude (Estimé)
1 décembre 2026
Dates d'inscription aux études
Première soumission
25 avril 2026
Première soumission répondant aux critères de contrôle qualité
25 avril 2026
Première publication (Réel)
1 mai 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
1 mai 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
25 avril 2026
Dernière vérification
1 avril 2026
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- P.T.REC/012/006406
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .